What is the primary purpose of this document for investors?

This document is a 10-Q filing, which provides investors with a periodic update on Gilead Sciences, Inc.'s financial performance and condition for the quarter ending May 30, 1996. It typically includes financial statements, management's discussion and analysis, and other material information.

What key financial information can I expect to find in the full 10-Q report?

The full 10-Q report would typically contain the company's balance sheets, income statements, cash flow statements, and notes to these financial statements. It would also include management's discussion and analysis (MD&A) of the financial condition and results of operations.

Given the early filing date (1996), what might be the focus of Gilead's operations during this period?

In 1996, Gilead Sciences was likely in its growth and development phase, focusing heavily on research and development for antiviral therapies. Investors would be looking for information on their pipeline progress, clinical trial updates, any early-stage product approvals or commercialization efforts, and their burn rate for R&D expenses.

Where can I find the actual financial data and analysis that is missing from this excerpt?

To get the detailed financial data and analysis, you would need to locate the full text of the 10-Q filing for the period ending May 30, 1996, on the SEC's EDGAR database or through a financial data provider that archives historical filings.

GILD 10-Q Quarterly Report Q2 FY1996 — Revenue, Net Income, EPS

Summary

This 10-Q filing from Gilead Sciences, Inc. (GILD) for the period ending May 30, 1996, represents an early stage of the company's financial reporting as a public entity. While specific financial figures and operational details are not readily available within the provided text (which appears to be primarily navigational metadata from the SEC EDGAR system rather than the full report content), investors should recognize this as a snapshot from a pivotal time in biotech's development. The filing would typically detail the company's financial position, results of operations, and cash flows, offering insights into its progress in developing its drug pipeline, research and development expenditures, and any early revenue streams or market penetration. Investors should seek the full report content to understand the company's financial health and strategic direction at that time.

Key Highlights

1This filing is a Quarterly Report (10-Q) for Gilead Sciences, Inc. (GILD).
2The reporting period concluded on May 30, 1996.
3The filing was submitted on July 25, 1996, indicating its historical context.
4The provided text is largely navigational metadata from the SEC EDGAR system.
5Full financial statements and operational details are not present in this excerpt.
6Investors would need to access the complete 10-Q filing for comprehensive financial analysis.
7This filing provides a historical glimpse into Gilead's financial reporting in the mid-1990s.

GILEAD SCIENCES, INC. Quarterly Report for Q2 Ended May 31, 1996

Summary

Key Highlights

Frequently Asked Questions